Drugs / Oleclumab
Trials 29
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT04261075 | Mar 2020 → Jun 2022 | neoplasm | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT03801902 | Oct 2019 → Oct 2021 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT03773666 | Feb 2019 → Feb 2021 | urinary bladder carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT03819465 | Dec 2018 → May 2023 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03736473 | Nov 2018 → Jun 2019 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02740985 | Jun 2016 → Dec 2020 | castration-resistant prostate carcinoma, colorectal carcinoma, high grade malignant neoplasm, non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02503774 | Jul 2015 → Jan 2021 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/25 trials · 3 missed | ||||||
| Phase 1/2 | NCT04068610 | Sep 2019 → Oct 2022 overdue | colorectal cancer | MedImmune LLC | Active not recruiting | Missed primary |
| Phase 1/2 | NCT03616886 | Dec 2018 → May 2021 overdue | triple-negative breast carcinoma | Jules Bordet Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03742102 | Dec 2018 → Nov 2024 overdue | triple-negative breast carcinoma | AstraZeneca | Active not recruiting | Missed primary |
| Phase 1/2 | NCT03611556 | Jun 2018 → Jul 2022 | pancreatic adenocarcinoma | MedImmune LLC | Completed | Missed primary |
| Phase 1/2 | NCT03381274 | May 2018 → May 2021 overdue | non-small cell lung carcinoma | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 216 trials · 1 missed | ||||||
| Phase 2 | NCT07146230 | Sep 2026 → Apr 2028 expected | non-small cell lung carcinoma | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06606847 | Sep 2024 → May 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06060405 | Nov 2023 → Oct 2026 expected | pancreatic ductal adenocarcinoma | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2 | NCT05061550 | Apr 2022 → May 2030 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT04940286 | Sep 2021 → Oct 2027 expected | pancreatic adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04262375 | Jan 2021 → Jan 2024 | non-small cell lung carcinoma, renal cell carcinoma | University Health Network, Toronto | Withdrawn | No outcome recorded |
| Phase 2 | NCT04262388 | Jan 2021 → Jan 2023 | head and neck squamous cell carcinoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | University Health Network, Toronto | Withdrawn | No outcome recorded |
| Phase 2 | NCT04668300 | Nov 2020 → Jun 2027 expected | angiosarcoma, dedifferentiated liposarcoma, osteosarcoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04145193 | Oct 2020 → Mar 2024 | colorectal cancer | MedImmune LLC | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03875573 | Nov 2019 → Nov 2024 overdue | luminal B breast carcinoma | Jules Bordet Institute | Active not recruiting | Missed primary |
| Phase 2 | NCT03833440 | Oct 2019 → Oct 2024 | non-small cell lung carcinoma | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 2 | NCT04089553 | Aug 2019 → Jun 2021 | castration-resistant prostate carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT03794544 | Mar 2019 → Jan 2021 | non-small cell lung carcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT03822351 | Dec 2018 → Jul 2023 | non-small cell lung carcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT03267589 | May 2018 → Oct 2021 | ovarian cancer | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Completed | No outcome recorded |
| Phase 2 | NCT03334617 | Dec 2017 → Sep 2024 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05221840 | Feb 2022 → Sep 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-03-28 | AstraZeneca | Results AstraZeneca aims to transform the oncology treatment landscape with diverse early pipeline and novel combinations at AACR astrazeneca.com ↗
A presentation from the NeoCOAST randomised Phase II trial in resectable, early-stage non-small cell lung cancer will highlight improved disease responses with novel Imfinzi (durvalumab) combinations including with oleclumab, an anti-CD73 monoclonal antibody, and with monalizumab 1 , an anti-NKG2A checkpoint inhibitor, when compared to Imfinzi alone. |
| 2021-09-17 | AstraZeneca | Results Imfinzi combined with novel immunotherapies improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer astrazeneca.com ↗
The 10-month PFS rate was 64.8% for the durvalumab plus oleclumab combination and 72.7% for durvalumab plus monalizumab, versus 39.2% with durvalumab alone. |
All press releases naming this drug 2 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oleclumab | “A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or...” NCT03616886 ↗ |
| Known as | MEDI9447 | “This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab in patients with advanced colorectal...” PMID 37016126 ↗ Apr 20237“durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201)” NCT05221840 ↗ “durvalumab (MEDI4736) in combination with oleclumab (MEDI9447)” NCT06606847 ↗ “Intervention: MEDI9447 (CD73) + durvalumab” NCT03267589 ↗ “Oleclumab (MEDI9447)” NCT03833440 ↗ |
| Known as | Oleclumab (MEDI-9447) | “Oleclumab (MEDI-9447)” NCT03822351 ↗ |
| Action | Inhibit | “MEDI9447 is a potent inhibitor of CD73 ectonucleotidase activity” PMID 27622077 ↗ Jul 2016 |
| Modality | Monoclonal antibody | “First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.” PMID 37016126 ↗ Apr 2023 |
| Route | Intravenous | “Patients received oleclumab 5-40 mg/kg (dose-escalation) or 40 mg/kg (dose-expansion) intravenously every 2 weeks (Q2W), alone (escalation only) or with durvalumab 10 mg/kg...” PMID 37016126 ↗ Apr 2023 |
| Target | NT5E | “durvalumab plus oleclumab (anti-CD73)” PMID 37707791 ↗ Nov 2023 |